Should Women with Sickle Cell Disease be Administered Prophylactic Transfusions to Avoid Complications during Pregnancy?
Patricia Palcu(University of Toronto), Nadine Shehata(Mount Sinai Hospital), Ann Kinga Malinowski(Mount Sinai Hospital), Nusrat Zaffar(Target (United States)), Kevin H.M. Kuo(University Health Network), Richard Ward(University of Tennessee Health Science Center)
Cited by 0
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Online haemodiafiltration: definition, dose quantification and safety revisited
|Nephrology Dialysis Transplantation|2013|256
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162